Life Sciences Venture Fund aMoon Raises $600 Million for Second Fund, Report Says
The Israel-based firm first announced in April it was raising a second fund with a hard cap of $750 million
Israel-based life sciences, healthcare, and technology venture capital firm aMoon has received $600 million in commitments for its second fund, aMoon II, Reuters reported Wednesday. AMoon reported a $250 million commitment from Credit Suisse AG in May.
AMoon first announced it was raising a second fund in April 2018. The firm said the second fund will focus on mid to late-stage health companies in the domains of pharma, digital health, and medical technology. In November 2018, Calcalist reported that aMoon has passed its $500 million target for the fund and is close to its hard cap of $750 million, citing a Linkedin post by aMoon co-founder Yair Schindel.
Founded in 2016 by Schindel, the former CEO of Israel’s National Digital Bureau, and Marius Nacht, the co-founder of firewall pioneer Check Point Software Technologies Ltd., aMoon's first fund was backed exclusively by Nacht.